Preliminary Clinical Experience with 4’-Epidoxorubicin in Advanced Human Neoplasia
- 1 January 1980
- book chapter
- Published by Springer Nature
- Vol. 74, 192-199
- https://doi.org/10.1007/978-3-642-81488-4_24
Abstract
4’-Epidoxorubicin (epi-DXR) was tested in 56 patients with various types of advanced malignancies. The pattern of acute toxicity was similar to that of doxorubicin (DXR), but epi-DXR produced a lower incidence of vomiting, stomatitis, alopecia, and myelosuppression. The study of cardiac toxicity, utilizing only noninvasive methods, indicated that epi-DXR also is cardiotoxic. The increase in the systolic time intervals after the first dose as well as after cumulative doses was slightly lower compared with that observed after DXR. Antitumor activity occurred in a variety of tumors including malignant melanoma, renal cancer, and rectal cancer, which are refractory to DXR. Present results suggest that further studies with epi-DXR are indicated.Keywords
This publication has 5 references indexed in Scilit:
- Systolic time interval as index of schedule--dependent doxorubicin cardiotoxicity in patients with acute myelogenous leukaemia.BMJ, 1979
- Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moietyChemico-Biological Interactions, 1977
- Adriamycin Cardiotoxicity in ManAnnals of Internal Medicine, 1974
- AdriamycinAnnals of Internal Medicine, 1974
- Bedside technics for the evaluation of ventricular function in manThe American Journal of Cardiology, 1969